Sort   by:  
 Page size 
UnknownAntibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Not available
S-EPMC11145656 | biostudies-literature
UnknownFc receptor engagement of HIV-1 Env-specific antibodies in mothers and infants predicts reduced vertical transmission.
Not available
S-EPMC9791209 | biostudies-literature
UnknownB cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.
Not available
S-EPMC8245051 | biostudies-literature
UnknownSARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
Not available
S-EPMC8132231 | biostudies-literature
UnknownRV144 HIV-1 vaccination impacts post-infection antibody responses.
Not available
S-EPMC7748270 | biostudies-literature
UnknownSARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
Not available
S-EPMC8651551 | biostudies-literature
UnknownLongitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.
Not available
S-EPMC6555550 | biostudies-literature
UnknownA SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.
Not available
S-EPMC8219092 | biostudies-literature
UnknownEfficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
Not available
S-EPMC8463842 | biostudies-literature
UnknownA SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.
Not available
S-EPMC8553838 | biostudies-literature
Sort   by:  
 Page size